Atlas Trials

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Clinical trial NCT05594927 · RECRUITING

Trial details

NCT number
NCT05594927
Sponsor
Beijing Shenogen Biomedical Co., Ltd
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2022-12-12
Primary completion
2025-08-30
Enrollment
261

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.